| Nov 18 |
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
|
| Nov 14 |
MBX Biosciences: Decent Potential For Lead Indication, But Need More Data
|
| Nov 7 |
MBX Biosciences, Inc. GAAP EPS of -$2.78 misses by $0.18
|
| Nov 7 |
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Oct 28 |
MBX Biosciences to Participate in Upcoming November Investor Conferences
|
| Oct 14 |
Opening Day: Another trio of biotech IPOs make Friday debut
|
| Oct 8 |
MBX Bio drops despite bullish views on Street
|
| Sep 30 |
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
|
| Sep 27 |
Biotech IPOs return as sector recovers after funding overhang
|
| Sep 18 |
OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc
|
